Company Overview
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company focused on creating therapeutics for underserved medical conditions. The firm's specific areas of development include treatments for post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. This entity functions within the Healthcare sector, specifically the Biotechnology industry, which generally involves high research and development expenditures and long product development timelines. The company possesses a very limited operational scale, employing only three individuals and holding a market capitalization of $4.82 million. With annual revenue of $72,102, the firm's financial footprint is extremely small relative to its market capitalization, indicating a pre-revenue or early-stage status where valuation metrics are driven by potential rather than established earnings. The disparity between the $4.82 million market cap and the $72,102 in revenue highlights that the stock price reflects expectations of future clinical success rather than current operational performance. The minimal workforce of three employees suggests that the company relies heavily on external partnerships or a lean internal structure to manage its R&D initiatives while maintaining a low burn rate on personnel costs.
Financial Health
The company reported revenue of $72,102 over the trailing twelve months, yet it recorded a net income of -$5,076,788 and an EBITDA of -$5,295,894 during the same period. The substantial gap between the $72,102 in revenue and the -$5.08 million net loss reveals a cost structure dominated by non-revenue expenses, likely consisting of high clinical trial costs, regulatory filing fees, and research development overheads that far exceed current sales. Free cash flow stands at -$3,113,872, which indicates that the company is burning cash to fund its operations and development programs without generating sufficient cash from sales to cover these outflows. Despite the negative free cash flow, the company maintains a cash balance of $5.87 million, providing a finite runway for operations before requiring additional capital raising. The balance sheet shows a debt level listed as N/A, while the company holds $5.87 million in cash, creating a conservative liquidity profile despite the lack of traditional debt obligations. The current ratio is 8.70, a figure that indicates a highly liquid position where current assets significantly outweigh current liabilities, ensuring the ability to meet short-term obligations even with negative earnings. Return on Equity is -86.1% and Return on Assets is -44.4%, metrics that reveal that management has not yet generated positive returns on shareholder capital or the assets deployed for research. These negative return metrics are typical for developmental stage biotech firms but underscore the significant risk of capital erosion if development milestones are not met.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the net losses, while the forward P/E is -0.49, a negative figure that implies earnings are expected to remain negative or that the valuation model is adjusting for the lack of profitability. The price-to-book ratio is 0.71, which indicates that the market is valuing the company at a discount to its net asset value, suggesting investors are pricing in significant risks regarding the company's intangible assets and future prospects. The price-to-sales ratio is 66.80, a high multiple relative to the $72,102 in revenue that suggests the market is placing a premium on future potential rather than current sales performance. The enterprise value to EBITDA ratio is 0.25, an alternative valuation metric that further reflects the company's lack of profitability and the speculative nature of its current pricing. The stock's 52-week high is $1.39 and the 52-week low is $0.22, meaning the current trading price sits within a wide historical range that reflects high volatility and speculative trading interest. The beta value is 0.61, indicating that the stock's price volatility is lower than the broader market average, which is an unusual characteristic for a small-cap biotechnology firm with such a wide price range.
Growth & Income
Revenue growth year-over-year is 0.0% and earnings growth year-over-year is N/A, reflecting a flat top line that has not yet scaled beyond its current minimal levels. Since the company is in a developmental stage, the lack of earnings growth means that any future profitability would depend entirely on successful clinical outcomes rather than organic revenue expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings and cash reserves are being reinvested into research and development rather than distributed to shareholders. This reinvestment strategy is standard for early-stage biotechnology firms but means that shareholders must rely solely on potential stock appreciation rather than income generation for returns. The overall growth and income profile is characterized by zero current revenue growth, negative earnings, and no dividend income, presenting a high-risk, high-reward scenario dependent on future product approvals and market entry.